

Aneesh K Mehta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5531558/publications.pdf>

Version: 2024-02-01

92
papers

14,868
citations

94269

37
h-index

54797

84
g-index

95
all docs

95
docs citations

95
times ranked

27257
citing authors

#	ARTICLE	IF	CITATIONS
1	Remdesivir for the Treatment of Covid-19 – Final Report. New England Journal of Medicine, 2020, 383, 1813-1826.	13.9	5,834
2	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. New England Journal of Medicine, 2021, 384, 795-807.	13.9	1,398
3	Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. Journal of Experimental Medicine, 2011, 208, 181-193.	4.2	775
4	Systems biology of vaccination for seasonal influenza in humans. Nature Immunology, 2011, 12, 786-795.	7.0	749
5	Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Reports Medicine, 2020, 1, 100040.	3.3	421
6	Persistence of Ebola Virus in Ocular Fluid during Convalescence. New England Journal of Medicine, 2015, 372, 2423-2427.	13.9	399
7	Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9047-9052.	3.3	371
8	Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. Nature Immunology, 2016, 17, 1226-1234.	7.0	348
9	Clinical Management of Ebola Virus Disease in the United States and Europe. New England Journal of Medicine, 2016, 374, 636-646.	13.9	316
10	Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Reports Medicine, 2021, 2, 100354.	3.3	316
11	Clinical Care of Two Patients with Ebola Virus Disease in the United States. New England Journal of Medicine, 2014, 371, 2402-2409.	13.9	310
12	Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures. Immunity, 2015, 43, 1186-1198.	6.6	286
13	Human Ebola virus infection results in substantial immune activation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4719-4724.	3.3	274
14	Metabolic Phenotypes of Response to Vaccination in Humans. Cell, 2017, 169, 862-877.e17.	13.5	234
15	Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13133-13138.	3.3	197
16	The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. Clinical Infectious Diseases, 2015, 61, 496-502.	2.9	182
17	Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. Cell, 2019, 177, 1566-1582.e17.	13.5	153
18	CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCR β repertoire. Blood, 2015, 125, 3835-3850.	0.6	147

#	ARTICLE	IF	CITATIONS
19	Renal Transplantation Using Belatacept Without Maintenance Steroids or Calcineurin Inhibitors. <i>American Journal of Transplantation</i> , 2014, 14, 1142-1151.	2.6	114
20	Ebola virus disease: an update on post-exposure prophylaxis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e183-e192.	4.6	112
21	Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States. <i>Annals of Internal Medicine</i> , 2015, 163, 81-90.	2.0	109
22	Ebola Virus Persistence in Semen of Male Survivors. <i>Clinical Infectious Diseases</i> , 2016, 62, 1552-1555.	2.9	101
23	Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. <i>Clinical Infectious Diseases</i> , 2017, 65, 855-859.	2.9	101
24	InÂVivo T Cell Costimulation Blockade with Abatacept forÂAcute Graft-versus-Host Disease Prevention: A First-in-Disease Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1638-1649.	2.0	96
25	New filovirus disease classification and nomenclature. <i>Nature Reviews Microbiology</i> , 2019, 17, 261-263.	13.6	84
26	A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 2505-2516.	2.6	84
27	Acute Forms of Tuberculosis in Adults. <i>American Journal of Medicine</i> , 2009, 122, 12-17.	0.6	81
28	Influenza vaccineâ€œinduced human bone marrow plasma cells decline within a year after vaccination. <i>Science</i> , 2020, 370, 237-241.	6.0	77
29	Fecal Microbiota Transplantation for Refractory <i>Clostridium difficile</i> Colitis in Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2014, 14, 477-480.	2.6	73
30	Successful Delivery of RRT in Ebola Virus Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 31-37.	3.0	73
31	Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	70
32	The Allo- and Viral-Specific Immunosuppressive Effect of Belatacept, but Not Tacrolimus, Attenuates With Progressive T Cell Maturation. <i>American Journal of Transplantation</i> , 2014, 14, 319-332.	2.6	61
33	The Future of Flu: A Review of the Human Challenge Model and Systems Biology for Advancement of Influenza Vaccinology. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 107.	1.8	53
34	High CTLA-4 Expression on Th17 Cells Results in Increased Sensitivity to CTLA-4 Coinhibition and Resistance to Belatacept. <i>American Journal of Transplantation</i> , 2014, 14, 607-614.	2.6	50
35	Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease. <i>Clinical Infectious Diseases</i> , 2016, 63, 460-467.	2.9	50
36	The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders. <i>Transplantation</i> , 2012, 94, 784-793.	0.5	45

#	ARTICLE	IF	CITATIONS
37	Ebola Hemorrhagic Fever in 2014: The Tale of an Evolving Epidemic. <i>Annals of Internal Medicine</i> , 2014, 161, 746.	2.0	45
38	Multicenter comparison of laboratory performance in cytomegalovirus and <i>Epstein-Barr</i> virus viral load testing using international standards. <i>Clinical Transplantation</i> , 2014, 28, 1416-1423.	0.8	39
39	Broadly Reactive Human CD8 T Cells that Recognize an Epitope Conserved between VZV, HSV and EBV. <i>PLoS Pathogens</i> , 2014, 10, e1004008.	2.1	36
40	Comparison of FilmArray and Quantitative Real-Time Reverse Transcriptase PCR for Detection of Zaire Ebola virus from Contrived and Clinical Specimens. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2956-2960.	1.8	35
41	Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults. <i>Journal of Immunology</i> , 2017, 199, 604-612.	0.4	33
42	Long-term Management of Panuveitis and Iris Heterochromia in an Ebola Survivor. <i>Ophthalmology</i> , 2016, 123, 2626-2628.e2.	2.5	28
43	Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans. <i>Emerging Infectious Diseases</i> , 2019, 25, 290-298.	2.0	28
44	Transmission of Eastern Equine Encephalitis Virus From an Organ Donor to 3 Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019, 69, 450-458.	2.9	27
45	Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus. <i>Clinical Infectious Diseases</i> , 2016, 63, 376-379.	2.9	26
46	Bioaerosol sampling of a ventilated patient with COVID-19. <i>American Journal of Infection Control</i> , 2020, 48, 1540-1542.	1.1	25
47	Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five-year follow-up. <i>American Journal of Transplantation</i> , 2020, 20, 3609-3619.	2.6	25
48	Immunologic timeline of Ebola virus disease and recovery in humans. <i>JCI Insight</i> , 2020, 5, .	2.3	25
49	Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. <i>Transplant International</i> , 2013, 26, 592-600.	0.8	24
50	Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans. <i>Journal of Virology</i> , 2018, 92, .	1.5	23
51	Racial and Ethnic Differences and Clinical Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) Presenting to the Emergency Department. <i>Clinical Infectious Diseases</i> , 2022, 74, 387-394.	2.9	23
52	Efficacy of Alcohol-Based Hand Rubs in the Disinfection of Stethoscopes. <i>Infection Control and Hospital Epidemiology</i> , 2010, 31, 870-872.	1.0	21
53	<i>Fusarium falciforme</i> Vertebral Abscess and Osteomyelitis: Case Report and Molecular Classification. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2350-2353.	1.8	21
54	Kinetics of antibody response to influenza vaccination in renal transplant recipients. <i>Transplant Immunology</i> , 2019, 53, 51-60.	0.6	20

#	ARTICLE	IF	CITATIONS
55	Avoidance of CNJ and steroids using belatacept—Results of the Clinical Trials in Organ Transplantation 16 trial. <i>American Journal of Transplantation</i> , 2020, 20, 3599-3608.	2.6	16
56	Clinical characteristics and outcomes of toxoplasmosis among transplant recipients at two US academic medical centers. <i>Transplant Infectious Disease</i> , 2021, 23, e13636.	0.7	12
57	Ebola Virus Disease: Implications for Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2015, 15, 5-6.	2.6	11
58	Deconstructing the Treatment Effect of Remdesivir in the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1: Implications for Critical Care Resource Utilization. <i>Clinical Infectious Diseases</i> , 2022, 74, 2209-2217.	2.9	11
59	Use of posaconazole in the treatment of invasive fungal infections. <i>Expert Review of Hematology</i> , 2009, 2, 619-630.	1.0	10
60	Invasive Fungal Sinusitis due to Mucor Species in a Patient on Ibrutinib. <i>Clinical Infectious Diseases</i> , 2018, 66, 1482-1483.	2.9	10
61	Cryptococcus transmission through solid organ transplantation in the United States: A report from the Ad Hoc Disease Transmission Advisory Committee. <i>American Journal of Transplantation</i> , 2021, 21, 1911-1923.	2.6	10
62	HIV-Associated Histoplasmosis in a Nonendemic Area of the United States During the HAART Era: Role of Migration From Endemic Areas and Lack of Antiretroviral Therapy. <i>Journal of the International Association of Providers of AIDS Care</i> , 2010, 9, 296-300.	1.2	9
63	Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. <i>Journal of Experimental Medicine</i> , 2011, 208, 411-411.	4.2	9
64	TIGIT regulates apoptosis of risky memory T cell subsets implicated in belatacept-resistant rejection. <i>American Journal of Transplantation</i> , 2021, 21, 3256-3267.	2.6	9
65	Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine. <i>Journal of Infectious Diseases</i> , 2018, 217, 1055-1059.	1.9	8
66	Donor derived hepatitis B virus infection: Analysis of the Organ Procurement & Transplantation Network/United Network for Organ Sharing <i>Ad Hoc</i> Disease Transmission Advisory Committee. <i>Transplant Infectious Disease</i> , 2021, 23, e13458.	0.7	8
67	Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients. <i>Journal of Clinical Microbiology</i> , 2021, , JCM0016121.	1.8	7
68	National Landscape of Human Immunodeficiency Virus—Positive Deceased Organ Donors in the United States. <i>Clinical Infectious Diseases</i> , 2022, 74, 2010-2019.	2.9	7
69	Early steps to kidney transplantation among persons with HIV and end-stage renal disease in ESRD network 6. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	7
70	Infectious Diseases in End-Stage Liver Disease Patients. <i>Critical Care Nursing Clinics of North America</i> , 2010, 22, 291-307.	0.4	6
71	Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines. <i>Health Security</i> , 2019, 17, 46-53.	0.9	5
72	Lassa Virus Infection: a Summary for Clinicians. <i>International Journal of Infectious Diseases</i> , 2022, 119, 187-200.	1.5	5

#	ARTICLE	IF	CITATIONS
73	Serosurvey on healthcare personnel caring for patients with Ebola virus disease and Lassa virus in the United States. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 385-390.	1.0	4
74	Contributions of the Regional Emerging Special Pathogen Treatment Centers to the US COVID-19 Pandemic Response. <i>Health Security</i> , 2022, 20, S-4-S-12.	0.9	4
75	Development, implementation and evaluation of a fourth-year medical school elective course in clinical microbiology using case-based vignettes. <i>Journal of Medical Microbiology</i> , 2013, 62, 1098-1110.	0.7	3
76	Clinical Management of Patients with Ebola Virus Disease in High-Resource Settings. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 115-137.	0.7	3
77	Adenovirus causing hepatic abscess formation and unexplained fever in adult liver transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13435.	0.7	3
78	Human Adenovirus 11 in 2 Renal Transplant Recipients: Suspected Donor-Derived Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab092.	0.4	3
79	Tacrolimus concentration to dose ratio in solid organ transplant patients treated with fecal microbiota transplantation for recurrent <i>Clostridium difficile</i> infection. <i>Transplant Infectious Disease</i> , 2018, 20, e12857.	0.7	2
80	The Evolution of the National Special Pathogen System of Care. <i>Health Security</i> , 2022, 20, S-39-S-48.	0.9	2
81	A First-in-Disease Trial of in Vivo Costimulation Blockade for GVHD Prevention: The Addition of Abatacept to Standard GVHD Prophylaxis Controls Early CD4+ T Cell Proliferation and is Associated with Low Rates of Severe Acute GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S327-S328.	2.0	1
82	646. Activated Macrophages as Pathogenesis Factors in Ebola Virus Disease in Humans. <i>Open Forum Infectious Diseases</i> , 2018, 5, S234-S234.	0.4	1
83	Answer to May 2021 Photo Quiz. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	1
84	A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD. <i>Blood</i> , 2012, 120, 741-741.	0.6	1
85	Unravelling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	1
86	Exhaustive TCR Deep Sequencing Reveals That CMV Reactivation Fundamentally Resets Immune Reconstitution after Transplant and Results in Significant Deficits in the Effector Memory TCR Repertoire. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S69-S70.	2.0	0
87	1733. 10 Years of DTAC Experience With Donor-Derived <i>Cryptococcus</i> Transmission in Solid-Organ Transplantation in the United States. <i>Open Forum Infectious Diseases</i> , 2018, 5, S59-S59.	0.4	0
88	1770. Access to Kidney Transplantation in Persons Living with HIV and End-stage Renal Disease in Network 6. <i>Open Forum Infectious Diseases</i> , 2019, 6, S652-S653.	0.4	0
89	2693. Clinical Presentation of Toxoplasmosis and 30-Day Mortality in Transplant Recipients at Two Academic Medical Centers. <i>Open Forum Infectious Diseases</i> , 2019, 6, S946-S947.	0.4	0
90	Photo Quiz: Strength in Numbers—A Disseminated Infection Causing Shortness of Breath. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	0

#	ARTICLE	IF	CITATIONS
91	Reply to author. <i>Clinical Infectious Diseases</i> , 2022, 74, 556-556.	2.9	0
92	1078. Renal Transplant Recipient Resistomes Reveal Expansive Sub-Clinical Burden of Resistance After Treatment for ESBL-Producing Bacterial Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, S566-S567.	0.4	0